CGEN.TA - Compugen Ltd.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
1,955.00
+3.00 (+0.15%)
As of 10:53AM IST. Market open.
Stock chart is not supported by your current browser
Previous Close1,952.00
Open1,967.00
Bid1,934.00 x 1500
Ask1,946.00 x 200
Day's Range1,955.00 - 1,967.00
52 Week Range800.00 - 2,170.00
Volume613
Avg. Volume17,349
Market Cap1.22B
Beta (3Y Monthly)2.66
PE Ratio (TTM)N/A
EPS (TTM)-0.49
Earnings DateNov 7, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Compugen Reports Third Quarter 2019 Results

    Preliminary Phase 1 clinical data presented at SITC 2019 demonstrate COM701 is well-tolerated with initial signals of anti-tumor activity Initiation of COM902 Phase 1 study in patients with advanced malignanciesplanned ...

  • PR Newswire

    Compugen Expands Patent Portfolio for COM902 with New Composition of Matter and Use Patent in Europe

    HOLON, Israel, Nov. 6, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that The European Patent Office (EPO) has granted a new patent covering the composition of matter and use of COM902, its immuno-oncology therapeutic antibody targeting TIGIT. EPO Patent No. EP3347379, titled "Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof," relates to the composition of matter of COM902, alone or in combination with a second antibody targeting an immune checkpoint, including PD-1 and PVRIG (specifically COM701). The patent further relates to COM902 for use in treating cancer by activating T cells, a key driver of immune stimulation and cancer immunotherapy treatments.

  • PR Newswire

    Compugen Presents Preclinical Data for COM902 Anti-TIGIT Program at SITC 2019

    Data support potential clinical use as a cancer immunotherapy treatment in various combinations with COM701 and PD-1 inhibitors HOLON, ISRAEL , Nov. 5, 2019 /PRNewswire/ --  Compugen Ltd.  (Nasdaq: CGEN), ...

  • PR Newswire

    Compugen Presents Initial Clinical Data from Ongoing Phase 1 Trial of COM701 in Patients with Advanced Solid Tumors at SITC 2019

    HOLON, Israel, Nov. 5, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today disclosed preliminary results from its ongoing Phase 1 dose escalation study of COM701, a first-in-class anti-PVRIG antibody, in patients with advanced solid tumors. COM701 was well-tolerated with no dose-limiting toxicities observed. Furthermore, COM701 demonstrated initial signals of anti-tumor activity in the heavily pretreated patient population enrolled on the study.

  • PR Newswire

    Compugen Announces FDA Clearance of IND Application for COM902

    HOLON, ISRAEL, Nov. 4, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the U.S. Food and Drug Administration has cleared its investigational new drug (IND) application for COM902, its immuno-oncology therapeutic antibody targeting TIGIT in patients with advanced malignancies. Under this IND, the Company intends to initiate a Phase 1 clinical trial in patients with advanced malignancies for whom standard of care therapies are currently ineffective. Expected to begin in early 2020, the clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of COM902.

  • PR Newswire

    Compugen to Release Third Quarter 2019 Results on Monday, November 11, 2019

    HOLON, Isreal, Oct. 28, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will ...

  • PR Newswire

    Compugen to Present Data from Ongoing COM701 Phase 1 Clinical Trial at SITC 2019

    HOLON, Israel, Oct. 2, 2019 /PRNewswire/ -- October 2, 2019 – Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced it will present three posters at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019) to be held November 6-10 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland.

  • PR Newswire

    Compugen Presents Update on COM701 Phase 1 Study at 2019 IGCS

    In a poster titled "COM701 (A Novel Immune Checkpoint Inhibitor) in Patients with Advanced Solid Tumors," the Company reported that it has completed enrollment in the seventh dose level in the COM701 monotherapy (Arm A) and second dose level in the combination of COM701 with Opdivo® (Nivolumab) (Arm B) and that no dose-limiting toxicities were observed in these and prior dose level cohorts. COM701 as a monotherapy and in combination with Opdivo has shown an acceptable safety and tolerability profile at all dose levels tested.

  • Thomson Reuters StreetEvents

    Edited Transcript of CGEN.TA earnings conference call or presentation 5-Aug-19 12:30pm GMT

    Q2 2019 Compugen Ltd Earnings Call

  • Compugen Ltd. (CGEN) Q2 2019 Earnings Call Transcript
    Motley Fool

    Compugen Ltd. (CGEN) Q2 2019 Earnings Call Transcript

    CGEN earnings call for the period ending June 30, 2019.

  • PR Newswire

    Compugen Reports Second Quarter 2019 Results

    HOLON, Israel , Aug. 5, 2019 /PRNewswire/ -- Compugen Ltd.  ( Nasdaq: CGEN ), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today reported financial ...

  • PR Newswire

    Compugen Second Quarter 2019 Conference Call Scheduled for Monday, August 5, 2019 at 8:30 AM ET

    HOLON, ISRAEL , July 22, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN ), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that ...

  • PR Newswire

    Compugen Expands Intellectual Property Portfolio for COM701 with New U.S. Patent Covering Combination Use with anti-PD-1 Antibody

    Previously granted U.S. Patent protects combination of COM701 and COM902 HOLON, Israel , July 16, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader ...

  • PR Newswire

    Compugen Appoints Eran Perry to Its Board of Directors

    HOLON, Israel, July 2, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced the appointment of Mr. Eran Perry to its board of directors, effective July 1, 2019. In addition, the Company announced that Yair Aharonowitz, Ph.D. and Arie Ovadia, Ph.D. will retire from its board of directors and will not be brought for re-election at the next annual general meeting. "Eran is an accomplished business leader with over 20 years of experience in the healthcare industry as well as general management, strategy and finance.

  • PR Newswire

    Compugen Presents Update on COM701 Phase 1 Trial at the 2019 ASCO Annual Meeting

    HOLON, Israel, June 3, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, was featured in a trial-in-progress poster at the 2019 ASCO Annual Meeting in Chicago, IL. In a poster (Abstract #TPS2657), titled "A phase I study evaluating COM701 in patients with advanced solid tumors," the Company reported that the sixth patient dose cohort of COM701 monotherapy has been completed and that no dose-limiting toxicities were observed in this and prior dose cohorts. The poster is available on Compugen's website at www.cgen.com.

  • Thomson Reuters StreetEvents

    Edited Transcript of CGEN.TA earnings conference call or presentation 20-May-19 12:30pm GMT

    Q1 2019 Compugen Ltd Earnings Call

  • PR Newswire

    Compugen to Present at the Jefferies 2019 Healthcare Conference

    HOLON, Israel , May 22, 2019 /PRNewswire/ -- Compugen Ltd.  (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that ...

  • GuruFocus.com

    Stocks Close Lower on Monday

    Compugen reports 1st-quarter results

  • Compugen Ltd. (CGEN) Q1 2019 Earnings Call Transcript
    Motley Fool

    Compugen Ltd. (CGEN) Q1 2019 Earnings Call Transcript

    CGEN earnings call for the period ending March 31, 2019.

  • Associated Press

    Compugen: 1Q Earnings Snapshot

    On a per-share basis, the Holon, Israel-based company said it had a loss of 14 cents. The company's shares closed at $3.46. A year ago, they were trading at $3.25. _____ This story was generated by Automated ...

  • PR Newswire

    Compugen Reports First Quarter 2019 Results

    HOLON, Israel , May 20, 2019 /PRNewswire/ -- Compugen Ltd.  (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today reported financial ...

  • PR Newswire

    Compugen Doses First Patient in COM701/Opdivo® (Nivolumab) Combination Arm of Phase 1 Study in Patients With Advanced Solid Tumors

    HOLON, Israel, May 20, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that it has dosed the first patient in the combination arm of its Phase 1 study, combining escalating doses of COM701 with a fixed dose of Opdivo® (nivolumab) in patients with advanced solid tumors. "Our successful progression through the COM701 monotherapy dose escalation arm, enabled us to initiate the combination study with COM701 and Opdivo," stated Anat Cohen-Dayag, Ph.D., President and CEO of Compugen.

  • PR Newswire

    Compugen First Quarter 2019 Conference Call Scheduled for Monday, May 20, 2019 at 8:30 AM ET

    HOLON, Israel , May 6, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that ...

  • PR Newswire

    Compugen Presents Update on COM701 Phase 1 Trial at the 2019 AACR Annual Meeting

    HOLON, Israel, April 3, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, was featured in a trial-in-progress poster at The 2019 AACR Annual Meeting in Atlanta, GA. In a poster titled "Phase I study of COM701 (a novel checkpoint inhibitor of PVRIG) in patients with advanced solid tumors", the Company reported that the fifth dose level patient cohort of COM701 monotherapy has been completed and that no dose-limiting toxicities were reported. The poster presented at the meeting is available on Compugen's website.

  • PR Newswire

    Compugen Announces Purchase of Company Shares by its Board of Directors and Members of Management

    "My fellow board members and I are excited about Compugen's unique value proposition, its proven computational discovery platform, and differentiated therapeutic pipeline that is designed to address significant unmet needs in immuno-oncology," said Paul Sekhri, Chairman of the Board. "We have the highest confidence in this management team and employees whose talent and dedication made possible the acomplishments of 2018, including the intiation of two clinical trials as well as partnerships with Bristol-Myers Squibb and AstraZeneca.